[Dose-effect relation of oral orciprenaline in obstructive respiratory diseases].
D001794:Blood Pressure / Q000187:drug effects; D001991:Bronchitis / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004646:Emphysema / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D010991:Plethysmography; D012118:Resorcinols / Q000008:administration & dosage* / Q000009:adverse effects; D013268:Stimulation, Chemical; D013610:Tachycardia / Q000139:chemically induced; D014202:Tremor / Q000139:chemically induced
D001993:Bronchodilator Agents; D010919:Placebos; D012118:Resorcinols
Die Dosis-Wirkungs-Relation von peroral verabreichtem Orciprenalin bei obstruktiven Atemwegserkrankungen.